日报更新时间：07-02 06:53
周报更新时间：01-23 11:54
今开价：
最高价：
成交量：
昨收价：
最低价：
最新价：
中文名称：美制药
英文名称：MEI Pharma
简介：MEI Pharma, Inc.,是一家处于发展阶段的抗肿瘤公司，专注于针对癌症的新型疗法的临床开发
电话：1-858-3697100,1-858-7926300
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2018-08-06 | Urso David M | Chief Operating Officer | Sell | 9500 | 3.58 |
| 2018-08-05 | Gold (Daniel P) | Officer and Director | Sell | 50938 | 3.75 |
| 2018-08-05 | Mass (Robert D) | Officer | Sell | 17709 | 3.75 |
| 2018-08-05 | Urso David M | Chief Operating Officer | Sell | 17764 | 3.75 |
| 2018-03-28 | Gold (Daniel P) | Chief Executive Officer | Sell | 128920 | 2.07 |
| 2017-11-26 | Baltic (Charles V III) | Director | Sell | 11000 | 2.21 |
| 2017-11-26 | Baltic (Charles V III) | Director | Buy | 11000 | 2.25 |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Bailard Inc | 503292 | 0.71% | 122000 | 32.00% | 2019-03-31 |
| Sio Capital Management, LLC | 2356633 | 3.31% | -17208 | -0.72% | 2019-03-31 |
| Vanguard Group Inc | 2504623 | 3.51% | 99706 | 4.15% | 2019-03-31 |
| Bvf Inc | 2698755 | 3.79% | -279953 | -9.40% | 2019-03-31 |
| Boxer Capital LLC | 2913091 | 4.09% | -- | -- | 2019-03-31 |
| Caxton Corp | 3459124 | 4.85% | -- | -- | 2019-03-31 |
| Perceptive Advisors LLC | 4400440 | 6.17% | -- | -- | 2019-03-31 |
| NEA Management Company, LLC | 5720572 | 8.02% | -- | -- | 2019-03-31 |
| Vivo Capital, LLC | 5778106 | 8.11% | -- | -- | 2019-03-31 |
| BlackRock Fund Advisors | 2298191 | 3.22% | 2915 | 0.13% | 2019-07-31 |
| Renaissance Technologies Corp | 2125013 | 2.98% | -198700 | -8.55% | 2019-03-31 |
| Vanguard Investments Australia Ltd | 1982270 | 2.78% | -- | -- | 2019-07-31 |
| Candriam Belgium | 510000 | 0.72% | -- | -- | 2019-07-31 |
| Candriam Luxembourg S.C.A. | 510000 | 0.72% | -- | -- | 2019-03-31 |
| BlackRock Inc | 597167 | 0.84% | 8534 | 1.45% | 2019-03-31 |
| Delaware Management Company | 600000 | 0.84% | -- | -- | 2019-07-31 |
| Macquarie Group Ltd | 600000 | 0.84% | -- | -- | 2019-03-31 |
| Indus Capital Partners, LLC | 631513 | 0.89% | -- | -- | 2019-03-31 |
| Millennium Management LLC | 693133 | 0.97% | 491548 | 243.84% | 2019-03-31 |
| Wasatch Advisors Inc. | 1109571 | 1.56% | 380531 | 52.20% | 2019-03-31 |
| Fosun International Ltd | 396526 | 0.56% | -- | -- | 2019-03-31 |
| Geode Capital Management, LLC | 522556 | 0.73% | 282013 | 117.24% | 2018-12-31 |
| Candriam Luxembourg | 510000 | 0.72% | -- | -- | 2019-03-31 |
| Hauck & Aufh | 396526 | 0.56% | -- | -- | 2019-04-30 |
| Dimensional Fund Advisors, Inc. | 388266 | 0.55% | -57432 | -12.89% | 2018-12-31 |
| Connor Clark & Lunn Inv Mgmt Ltd | 355614 | 0.50% | 4089 | 1.16% | 2018-09-30 |
| EAM Investors, LLC | 373889 | 0.53% | 536 | 0.14% | 2018-09-30 |
| Opus Point Partners Management, LLC | 360000 | 0.51% | -40000 | -10.00% | 2018-09-30 |
| Walleye Trading LLC | 449443 | 0.63% | 342501 | 320.27% | 2018-06-30 |
| BlackRock Institutional Trust Company NA | 387993 | 0.55% | -- | -- | 2018-06-30 |
| J.P. Morgan Securities Inc | 366819 | 0.52% | 366819 | -- | 2018-06-30 |
| ARONSON+JOHNSON+ORTIZ | 438710 | 0.62% | 337759 | 334.58% | 2018-03-31 |
| JPMorgan Chase & Co | 366819 | 0.52% | 366819 | -- | 2018-06-30 |
| Fidelity Management & Research Company | 435059 | 0.61% | -184749 | -29.81% | 2018-10-31 |
| EAM Investors | 373353 | 0.53% | 373353 | -- | 2018-06-30 |
| Longwood Capital Partners LLC | 880087 | 1.25% | 880087 | -- | 2018-06-30 |
| Renaissance Technologies LLC | 2014113 | 5.45% | 2014113 | -- | 2017-09-08 |
| Vivo Opportunity, LLC | 6600660 | 17.69% | 6600660 | -- | 2018-05-11 |
| New Enterprise Associates 16, LP | 7025641 | 9.99% | 7025641 | -- | 2018-05-16 |
| Medical Strategy GmbH | 319526 | 0.45% | 123049 | 62.63% | 2018-06-30 |
| Clarivest Asset Management LLC | 206600 | 0.55% | 4900 | 2.43% | 2018-03-31 |
| Oxford Asset Management, LLC | 226980 | 0.61% | -104098 | -31.44% | 2018-03-31 |
| TFS Capital LLC | 167442 | 0.46% | 66328 | 65.60% | 2017-07-31 |
| Apo Asset Management GmbH | 197625 | 0.28% | 43901 | 28.56% | 2018-07-31 |
| Jacobs Levy Equity Management, Inc. | 183447 | 0.49% | -6500 | -3.42% | 2018-03-31 |
| Deutsche Bank AG | 180213 | 0.48% | -47719 | -20.94% | 2018-03-31 |
| Acadian Asset Management LLC | 122259 | 0.33% | -27054 | -18.12% | 2018-03-31 |
| Ancora Advisors LLC | 167462 | 0.45% | -- | -- | 2018-03-31 |
| Algert Global LLC | 100140 | 0.27% | -133754 | -57.19% | 2018-03-31 |
| Northern Trust Investments N A | 73404 | 0.20% | -- | -- | 2017-12-31 |
| Morgan Stanley Smith Barney LLC | 76100 | 0.21% | -174900 | -69.68% | 2017-12-31 |
| Ad Valorem Research S.L. | 69874 | 0.19% | -412 | -0.59% | 2017-06-30 |
| Anson Funds Management LP | 486969 | 1.32% | 486969 | -- | 2016-12-31 |
| Macquarie Investment Management Limited | 96170 | 0.26% | -18055 | -15.81% | 2017-12-31 |
| Spark Investment Management LLC | 60700 | 0.16% | -1800 | -2.88% | 2017-09-30 |
| Two Sigma Investments LLC | 87583 | 0.24% | 87583 | -- | 2017-09-30 |
| Nationwide Fund Advisors | 85500 | 0.23% | 85500 | -- | 2017-09-30 |
| Helsinn Investment Fund SA | 2616431 | 7.66% | 2616431 | -- | 2016-08-16 |
| Vivo Ventures VII LLC | 2458995 | 7.20% | 2458995 | -- | 2016-04-06 |
| Bridgeway Capital Management, Inc | 427500 | 1.16% | -- | -- | 2016-09-30 |
| Iguana Healthcare Management, LLC | 300000 | 0.82% | 300000 | -- | 2016-09-30 |
| Goodwood Advisors, LLC | 150000 | 0.41% | -- | -- | 2016-12-31 |
| Vivo Ventures V, LLC | 142861 | 0.42% | 142861 | -- | 2016-04-06 |
| Victory Capital Management Inc. | 57642 | 0.16% | -- | -- | 2016-09-30 |
| Goldman, Sachs & Co. | 51429 | 0.14% | 28330 | 122.65% | 2016-09-30 |
| Connor Clark & Lunn Financial Group | 58675 | 0.16% | -- | -- | 2017-01-31 |
| Technical Financial Services LLC | 40382 | 0.11% | 40382 | -- | 2016-09-30 |
| Frigate Ventures LP | 1715000 | 10.00% | 2744000 | -- | 1999-11-30 |
| Vivo Ventures Funds, LLC | 3760136 | 10.00% | 6016218 | 0.10% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Alumot Equities Top Ideas | 200000 | 0.28% | 200000 | -- | 2019-05-31 |
| MEDICAL BioHealth | 396526 | 0.56% | -- | -- | 2019-04-30 |
| Vanguard Extended Market Index Fund | 397761 | 0.56% | -- | -- | 2019-06-30 |
| Candriam Eqs L Biotechnology | 510000 | 0.72% | -- | -- | 2019-06-30 |
| Delaware Healthcare Fund | 600000 | 0.84% | -- | -- | 2019-06-30 |
| iShares Russell 2000 Growth ETF | 617710 | 0.87% | -- | -- | 2019-07-30 |
| Wasatch Ultra Growth Fund | 1280035 | 1.80% | 175935 | 15.93% | 2019-06-30 |
| iShares Russell 2000 ETF | 1486878 | 2.09% | 2915 | 0.20% | 2019-07-30 |
| Vanguard Total Stock Market Index Fund | 1982270 | 2.78% | -- | -- | 2019-06-30 |
| BlackRock Russell 2500 | 91822 | 0.13% | 91822 | -- | 2019-06-30 |
| APO Medical Opportunities | 220157 | 0.31% | -- | -- | 2019-06-30 |
| Nationwide Bailard Tech&Sci Fund | 107792 | 0.15% | -- | -- | 2019-06-30 |
| iShares Micro-Cap ETF | 173834 | 0.24% | -- | -- | 2019-07-30 |
| Fidelity | 153139 | 0.21% | -- | -- | 2019-06-30 |
| Schwab Small Cap Index Fund | 141679 | 0.20% | 141679 | -- | 2019-06-30 |
| Russell 2000 Index Non-Lendable Fund E | 129193 | 0.18% | 129193 | -- | 2019-06-30 |
| The Vanguard - Russell 2000 Grwth Idx CF | 128041 | 0.18% | 128041 | -- | 2019-06-30 |
| Vanguard Balanced Index Fund | 93726 | 0.13% | 80600 | 614.05% | 2019-06-30 |
| iShares Russell 2000 Small-Cap Index Fd | 101748 | 0.14% | 101748 | -- | 2019-06-30 |
| Vanguard Instl Total Stock Market Idx Fd | 95949 | 0.13% | -- | -- | 2019-06-30 |
| BlackRock Russell 2000 | 85437 | 0.12% | 85437 | -- | 2019-06-30 |
| DFA US Core Equity II Fund | 83632 | 0.12% | -- | -- | 2019-05-31 |
| BlackRock Extended Equity Market | 73428 | 0.10% | -101 | -0.14% | 2019-06-30 |
| Acuitas US Microcap Fund | 56800 | 0.08% | 9000 | 18.83% | 2019-03-31 |
| RIM Global Bioscience | 52504 | 0.07% | -- | -- | 2019-05-31 |
| apo Medical Opportunities Institutionell | 52259 | 0.07% | -- | -- | 2019-05-31 |
| DFA US Small Cap Portfolio | 46324 | 0.06% | -- | -- | 2019-05-31 |
| ALPS Medical Breakthroughs ETF | 170290 | 0.24% | -- | -- | 2019-05-31 |
| PHARMA/wHEALTH | 44539 | 0.06% | -- | -- | 2018-07-31 |
| Variopartner SICAV - Pharma/wHealth | 44539 | 0.06% | -- | -- | 2018-12-31 |
| DFA US Core Equity 1 Portfolio | 37625 | 0.05% | -- | -- | 2018-12-31 |
| FCP MEDICAL BioHealth-Trends | 319526 | 0.45% | -- | -- | 2018-10-31 |
| Munda Valor Investments SICAV | 39917 | 0.06% | -93 | -0.23% | 2018-03-31 |
| DFA US Targeted Value Portfolio | 72586 | 0.10% | -- | -- | 2018-11-30 |
| GuideStone Funds Small Cap Equity Fund | 59107 | 0.08% | 59107 | -- | 2018-03-31 |
| Vanguard Global Equity Fund | 49908 | 0.07% | -10401 | -17.25% | 2018-03-31 |
| FCP MEDICAL BioHealth | 319526 | 0.45% | 123049 | 62.63% | 2018-06-30 |
| TFS Market Neutral Fund | 167442 | 0.24% | 66328 | 65.60% | 2017-07-31 |
| Nationwide Bailard Cognitive Value Fund | 78100 | 0.11% | -- | -- | 2017-10-31 |
| DFA US Core Equity 2 I | 83632 | 0.12% | -- | -- | 2018-07-31 |
| DFA US Vector Equity I | 20418 | 0.03% | -- | -- | 2018-07-31 |
| DFA Tax-Managed US Small Cap | 24871 | 0.04% | -- | -- | 2018-07-31 |
| DFA US Small Cap I | 25224 | 0.04% | -- | -- | 2018-07-31 |
| Russell US Small Cap Equity I | 31250 | 0.04% | -2800 | -8.22% | 2018-07-31 |
| Vanguard Total Stock Mkt Idx | 896606 | 1.27% | 15800 | 1.79% | 2018-07-31 |
| Vanguard Extended Market Idx Inv | 388861 | 0.55% | -- | -- | 2018-07-31 |
| Delaware Healthcare A | 310000 | 0.44% | 50000 | 19.23% | 2018-07-31 |
| Wasatch Ultra Growth | 213821 | 0.30% | 213821 | -- | 2018-06-30 |
| TFS Market Neutral | 167442 | 0.46% | 66328 | 65.60% | 2017-07-31 |
| iShares Micro-Cap | 95438 | 0.14% | -- | -- | 2018-09-12 |
| Acuitas US Microcap Institutional | 75900 | 0.11% | -15300 | -16.78% | 2018-06-30 |
| BlackRock Extended Equity Market K | 72929 | 0.10% | 1983 | 2.80% | 2018-06-30 |
| Vanguard Balanced Index Inv | 31611 | 0.04% | -- | -- | 2018-07-31 |
| DFA US Core Equity 1 I | 37625 | 0.05% | -- | -- | 2018-07-31 |
| Vanguard Instl Ttl Stk Mkt Idx InstlPls | 61287 | 0.09% | -- | -- | 2018-07-31 |
| Fidelity Spartan | 62189 | 0.09% | -- | -- | 2018-07-31 |
| Nationwide Bailard Tech&Sci M | 65000 | 0.09% | -- | -- | 2018-07-31 |
| DFA US Targeted Value I | 72586 | 0.10% | -- | -- | 2018-07-31 |
| Vanguard Global Equity Inv | 49908 | 0.13% | -10401 | -17.25% | 2018-03-31 |
| BNY Mellon EB DL Mkt Completion | 19577 | 0.03% | -- | -- | 2018-06-30 |
| iShares Core S&P Total US Stock Mkt | 13889 | 0.02% | -- | -- | 2018-07-12 |
| SA US Small Company | 13204 | 0.02% | -- | -- | 2018-06-30 |
| Wilshire Micro-Cap ETF | 10237 | 0.02% | -- | -- | 2018-07-05 |
| GuideStone Funds Small Cap Equity Instl | 59107 | 0.16% | 59107 | -- | 2018-03-31 |
| Quaker Small-Cap Value A | 32836 | 0.09% | -8200 | -19.98% | 2018-02-28 |
| DFA US Small Cap Value II | 19881 | 0.05% | -- | -- | 2017-12-31 |
| BNY Mellon Market Completion Fund UC1 | 19577 | 0.05% | 18385 | 1542.37% | 2017-09-30 |
| Bridgeway Ultra-Small Company | 427500 | 1.16% | -- | -- | 2016-09-30 |
| Goodwood SMID Cap Discovery A | 150000 | 0.41% | -- | -- | 2016-12-31 |
| Vericimetry U.S. Small Cap Value | 19100 | 0.05% | 19100 | -- | 2016-09-30 |
| The Vanguard Total Stock Market Index | 13200 | 0.04% | -- | -- | 2016-12-31 |
| USAA Extended Market Index | 8458 | 0.02% | -1 | -0.01% | 2016-09-30 |
| AXA/Lord Abbett Micro Cap K | 5118 | 0.01% | -- | -- | 2016-11-30 |
| Master Extended Market Index Series | 8459 | 0.02% | -- | -- | 2016-12-31 |
| Bridgeway Ultra Small Company Fund | 390000 | 1.10% | 192700 | 97.70% | 2015-09-30 |
| Fidelity Spartan® Extended Mkt Indx Fd | 92428 | 0.30% | -- | -- | 2015-09-30 |
| Vanguard Instl Total Stock Market Index | 48787 | 0.10% | -- | -- | 2015-10-31 |
| Fidelity Spartan® Total Market Idx Fund | 26819 | 0.10% | -- | -- | 2015-09-30 |
| BlackRock Extended Equity Market Fund | 17981 | -- | 17981 | -- | 2015-09-30 |
| The Vanguard - Total Stk Mkt Idx Trust. CF | 13200 | -- | -- | -- | 2015-10-31 |
| CC&L All Strategies | 7500 | -- | 700 | 10.30% | 2015-10-31 |
| Fidelity® NASDAQ Composite Index® Fund | 6684 | -- | -- | -- | 2015-09-30 |
| Fidelity® Small Cap Stock Fund | 617381 | 1.80% | -246919 | -28.60% | 2015-07-31 |
| Mellon Capital EB DL Mkt Completion Fund | 24836 | 0.10% | -- | -- | 2015-09-30 |
| Frederick W. Driscoll | Frederick W. Driscoll is on the board of NantKwest, Inc. and 4 other companies. Mr. Driscoll previously occupied the position of Chairman for Mateon Therapeutics, Inc., Chairman, President & Chief Executive Officer at Mateon Therapeutics, Inc., Chief Financial Officer at Astraris, Inc., Chief Financial Officer, Treasurer & VP at Novavax, Inc., Chief Financial Officer at Flexion Therapeutics, Inc., Senior Vice President-Finance & Operations at Collagenesis Corp., President & Chief Executive Officer of Genelabs Technologies, Inc. and Vice President-Finance-Americas & Controller at Instrumentation Laboratory Co. He received an undergraduate degree from Bentley University. |
|---|---|
| Richard G. Ghalie | Presently, Richard G. Ghalie holds the position of Senior Vice President-Clinical Development at MEI Pharma, Inc. He is also on the board of Viracta Therapeutics, Inc. In his past career Dr. Ghalie held the position of VP-Clinical Research & Regulatory Affairs at Poniard Pharmaceuticals, Inc., VP-Medical Affairs & Professional Services at Ligand Pharmaceuticals, Inc., Chief Medical Officer at Denovo Biopharma, Chief Medical Officer for Novalar Pharmaceuticals, Inc., Chief Medical Officer for Favrille, Inc., Chief Medical Officer for HemaQuest Pharmaceuticals, Inc., Senior Medical Director-Oncology Products at Immunex Corp. and Medical Director-Bone Marrow Transplant Center at Rush University Medical Center. Dr. Ghalie received an MBA from the University of Washington, a doctorate from St. Joseph's College and a graduate degree from Universit�0�1�0�8 Paris Diderot-Paris 7. |
| Kevan E. Clemens | Kevan E. Clemens is on the board of MEI Pharma, Inc. In his past career he held the position of Vice President for Specialty Care, Inc., Independent Director at Chelsea Therapeutics International Ltd., Head-Pharmacoeconomics & Pricing at de Syntex & Roche SA de CV and Executive Vice President & Business Director at Hoffmann-La Roche, Inc. Kevan E. Clemens received a doctorate from University College London. |
| Thomas C. Reynolds | Presently, Thomas C. Reynolds is President at Two Paddles Consulting LLC. Dr. Reynolds is also on the board of Trillium Therapeutics, Inc. and MEI Pharma, Inc. In the past Dr. Reynolds occupied the position of Chief Medical Officer for Seattle Genetics, Inc., Vice President-Medical Affairs for ZymoGenetics, Inc., Vice President-Clinical Affairs at Somatix Therapy Corp. and Vice President-Clinical Affairs at AmpliPhi Biosciences Corp. He received a doctorate from Stanford University and an undergraduate degree from Dartmouth College. |
| Charles V. Baltic | Charles V. Baltic is on the board of MEI Pharma, Inc. and SIDIS, Inc. In the past Mr. Baltic held the position of Managing Director at CRT Capital Group LLC, Managing Director-Healthcare Investment Banking at Wachovia Securities LLC, Member of US Securities & Exchange Commission and Director-Life Science at Cowen & Co. (New York). He received a graduate degree and an undergraduate degree from Georgetown University and an MBA from The Wharton School of the University of Pennsylvania. |
| Tamar D. Howson | Ms. Tamar D. Howson is an Independent Director at Organovo Holdings, Inc. She is on the Board of Directors at MEI Pharma, Inc., Organovo Holdings, Inc., International Partnership for Microbicides and Organovo, Inc. Ms. Howson was previously employed as an Independent Director by ContraVir Pharmaceuticals, Inc., an Independent Director by Enzymotec Ltd., an Independent Director by Cynapsus Therapeutics, Inc., an Independent Director by Cardax, Inc., an Independent Director by Actavis Plc, an Independent Director by Aradigm Corp., an Independent Director by Soligenix, Inc., an Independent Director by Mateon Therapeutics, Inc., an Independent Director by Idenix Pharmaceuticals LLC, a Principal by Howson Associates Ltd., a Member by JSB-Partners LP, an Executive Vice President-Corporate Development by Lexicon Pharmaceuticals, Inc., a Senior VP-Corporate & Business Development by Bristol-Myers Squibb Co., a Senior VP & Director-Business Development by GlaxoSmithKline Plc, a Senior VP & Director-Business Development by Smithkline Beecham Plc, a Vice President-Venture Investments by Johnston Associates, Inc., a Director-Worldwide Business Development by Squibb Corp., and a Chief Executive Officer & Director by S*BIO Pte Ltd. She also served on the board at Cardax Pharmaceuticals, Inc., Warner Chilcott Plc, Worldwide Business Development Corp., ARIAD Pharmaceuticals, Inc., BioLineRx Ltd., HBA Corp., Healthcare Businesswomens Association, NPS Pharmaceuticals, Inc., Pacira Pharmaceuticals, Inc. (California), SkyePharma Plc and Targacept, Inc. She received her undergraduate degree from Technion-Israel Institute of Technology, a graduate degree from The City College of New York and an MBA from Columbia University. |
| Brian G. Drazba | Brian G. Drazba is CFO, Secretary & Principal Accounting Officer at MEI Pharma, Inc. In the past Mr. Drazba occupied the position of Chief Financial & Accounting Officer, VP at Heron Therapeutics, Inc., Chief Accounting Officer & VP-Finance at ISTA Pharmaceuticals, Inc. and Chief Accounting Officer & Senior Vice President for InSight Health Services Holdings Corp. and Chief Accounting Officer & Senior Vice President for InSight Health Corp. (a subsidiary of InSight Health Services Holdings Corp.). Brian G. Drazba received an undergraduate degree from the University of San Diego. |
| Daniel P. Gold | Daniel P. Gold founded Favrille, Inc. and MMRGlobal, Inc. He is President, Chief Executive Officer & Director at MEI Pharma, Inc. Dr. Gold is also on the board of The Hope Funds for Cancer Research. In his past career Dr. Gold was President & Chief Executive Officer of Prospect Therapeutics, Inc., Managing Partner at Theragence, Inc., Chief Scientific Officer of Favrille, Inc. and Associate Professor at Sidney Kimmel Cancer Center. Dr. Gold received an undergraduate degree from the University of California, Los Angeles and a doctorate from Tufts University. |
| Nicholas R. Glover | Currently, Nicholas R. Glover is President, Chief Executive Officer & Director at Sierra Oncology, Inc. He is also on the board of MEI Pharma, Inc. In his past career Dr. Glover held the position of President, Chief Executive Officer & Director at Viventia Biotech, Inc., President, Chief Executive Officer & Director at YM BioSciences, Inc., Investment Manager at Lumira Capital Investment Management, Inc. and Investment Analyst at University Medical Discoveries, Inc. Dr. Glover received a doctorate from Simon Fraser University, an undergraduate degree from the University of East Anglia and a graduate degree from the University of British Columbia. |
| William Dodge Rueckert | William Dodge Rueckert is a businessperson who has been the head of 10 different companies. Presently, Mr. Rueckert is President & Director at Cleveland H. Dodge Foundation, Inc. and President of Oyster Management Group LLC. He is also Co-Chairman at Teachers College (New York) and Co-Chairman of Columbia University and on the board of 9 other companies. In his past career he was Non-Executive Chairman at Novagen Ltd., Chairman & Chief Executive Officer of Kazia Therapeutics Ltd., President & Director at Eastern Capital Development LLC, President & Director at Rosow & Co., Inc., Treasurer of Moore & Munger, Inc. and President for United States Oil Co. William Dodge Rueckert received an undergraduate degree from the University of New Hampshire. |
| Christine Anna White | Christine Anna White founded Apoptos, Inc. Currently, Dr. White is Non-Executive Chairman of MEI Pharma, Inc. In her past career Dr. White occupied the position of Senior Vice President-Global Medical Affairs at Biogen, Inc. and Vice President-Medical Affairs at IDEC Pharmaceuticals Corp. (a subsidiary of Biogen, Inc.), Director-Clinical Oncology Research at Sidney Kimmel Cancer Center and Chairman-Medicine Department at Scripps Memorial Hospital La Jolla. She received a doctorate and an undergraduate degree from The University of Chicago. |
| Robert D. Mass | Dr. Robert D. Mass, MD, is Chief Medical Officer at MEI Pharma, Inc. Dr. Mass was previously employed as Head-Medical Affairs by Genentech, Inc. He received his undergraduate degree from Tufts University and a doctorate degree from Oregon Health Sciences University. |
| David A. Walsey | Presently, David A. Walsey holds the position of VP-Investor Relations & Corporate Communications at MEI Pharma, Inc. Mr. Walsey previously was Vice President-Corporate communications at Alder Biopharmaceuticals, Inc., Director-Corporate Communications at Arena Pharmaceuticals, Inc., Senior Director-Investor Relations at Sarepta Therapeutics, Inc., VP-Investor Relations & Corporate Communications at Optimer Pharmaceuticals LLC and Head-Investor Relations & Corporate Communications at Maxim Pharmaceuticals, Inc. He received a graduate degree from New York University School of Law, a graduate degree from Brooklyn Law School and an undergraduate degree from Franklin & Marshall College. |
| David M. Urso | Founder of Tioga Pharmaceuticals, Inc., David M. Urso currently is COO, SVP-Corporate Development & General Counsel at MEI Pharma, Inc. In the past Mr. Urso was COO, Director & General Counsel at Tioga Pharmaceuticals, Inc., Principal at GlaxoSmithKline Plc, Attorney at Wilson Sonsini Goodrich & Rosati PC, Director-Corporate Development & Legal Affair at DNA Sciences, Inc., Attorney at Cooley Godward LLP and Principal at the University of Pennsylvania. He received an undergraduate degree from Reed College and a graduate degree from Harvard Law School. |
| Karen E. Potts | Karen E. Potts is Senior Vice President-Regulatory Affairs at MEI Pharma, Inc. In the past Dr. Potts held the position of Director-Regulatory Affairs at Ionis Pharmaceuticals, Inc., Associate Director-Regulatory Affairs at Pfizer Inc. Senior Research Scientist-Infectious Disease at G.D. Searle & Co. Ltd. and Senior Research Scientist-Virology at Agouron Pharmaceuticals LLC (both are subsidiaries of Pfizer Inc.), Senior Vice President-Regulatory Affairs at Trius Therapeutics, Inc. and Senior Director-Regulatory Policy at Allergan, Inc. Karen E. Potts received a doctorate from Emory University and an undergraduate degree from Smith College. |
| Robert D. Mass | Currently, Robert D. Mass is Chief Medical Officer of MEI Pharma, Inc. Dr. Mass previously was Head-Medical Affairs at Genentech, Inc. Dr. Mass received an undergraduate degree from Tufts University and a doctorate from Oregon Health Sciences University. |
| Ofir Moreno | Dr. Ofir Moreno is a Senior Vice President-Pharmaceutical Sciences at MEI Pharma, Inc. Dr. Moreno was previously employed as a Senior Director-Chemistry by Dendreon Corp. He received his undergraduate degree from Cornell University and a doctorate degree from Harvard University. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 1
MEI Pharma（MEIP.O）盘前涨超80%，此前与医药公司协和麒麟签订药物许可协议。